Pioneering the future of skin diagnostics
On the back of its innovative skin cancer detection device, Nevisense, SciBase has experienced significant revenue growth in recent years. With the company currently expanding into the US market, we find the potential for even higher revenue growth credible. However, the company has yet to turn a profit and has been, and likely continues to be, reliant on equity offerings to fund its operations. In addition, visibility into the complex US healthcare industry is poor, which makes predicting the timing of cash flow positivity an uncertain prospect. Therefore, while we have a strong positive outlook for the Nevisense device and anticipate high revenue growth, the above factors lead us to consider the share appropriately priced in the near term
Scibase Holding
SciBase Holding is a global medical technology group specialized in diagnostics and prevention in dermatology. The company develops, produces and commercializes Nevisense, a patient-centered platform that combines AI (artificial intelligence) with EIS technology to enable early detection and intervention of skin cancer and other skin diseases. Nevisense is based on over 20 years of research at Karolinska Institutet, the headquarters are in Stockholm.
Read more on company page